AbbVie Stock Inching Toward Highs Amid Drug Sale Talks

Citigroup raised its price target to $125 from $105

Deputy Editor
Mar 16, 2021 at 10:19 AM
facebook twitter linkedin


AbbVie Inc (NYSE:ABBV) is in the spotlight this morning, after news that the pharmaceutical company is in talks to sell a $5 billion portfolio of women's drugs. According to Reuters, the company acquired these drugs through its $63 billion purchase of Allergan this past year. Furthermore, Citigroup today raised its price target on the equity to $125 from $105. At last check, ABBV was up 0.5% to trade at $110.76.

On the charts, ABBV has been creeping up toward its recent Jan. 13 nearly three-year high of $113.41. A double layer of support looks to have formed at both the $102 level and 80-day moving average. Year-over-year, the equity is up 49%. 

Analysts are mostly bullish on AbbVie stock, with 12 of the 16 analysts in coverage at a "buy" or better rating. Plus, the 12-month consensus price target of $122.63 comes into today with a 10.8% premium to current levels. 

Sentiment is similar in the options pits. ABBV's 50-day call/put volume ratio of 3.69 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) stands higher than 91% of readings from the past year. This means long calls have been picked up at a much faster-than-usual rate over the last 10 weeks. 

Now might not be a bad time to weigh in on these options either. The stock's Schaeffer's Volatility Index (SVI) of 25% stands higher than just 9% of all other readings in its annual range, implying that options players are pricing in relatively low volatility expectations at the moment. 

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

 


 


 
Special Offers from Schaeffer's Trading Partners